EUVIMEDEUVIMED entdecken
Crossref

Combined Reverse-Transcriptase Multiplex Ligation-Dependent Probe Amplification and Next-Generation Sequencing Analyses to Assign Unclassified BCL2/BCL6 Nonrearranged Small B-Cell Lymphoid Neoplasms as Follicular or Nodal Marginal Zone Lymphoma

Come Sesboue, Jean Galtier, Marie Jeanneau, Annick Chauvel, Elodie Laharanne, Samuel Amintas, Jean-Philippe Merlio, Krimo Bouabdallah, François-Xavier Gros, Laurence de Leval, Audrey Gros, Marie Parrens

Modern Pathology · 2023

DOI: 10.1016/j.modpat.2022.100043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2023. Verfasst von Come Sesboue und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Department, University Hospital of Bordeaux, Pessac, France. Electronic address: come.sesboue@chu-bordeaux.fr. Hauptthemen laut MEDLINE: Lymphoma, B-Cell, Marginal Zone, Lymphoma, Follicular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Distinguishing between follicular lymphoma (FL) and nodal marginal zone lymphoma (NMZL) can be difficult when morphologic and phenotypic features are unusual and characteristic cytogenetic rearrangements are absent. We evaluated the diagnostic contribution of ancillary techniques-including fluorescence in situ hybridization (FISH)-detected 1p36 deletion; reverse-transcriptase, multiplex, ligation-dependent probe amplification (RT-MLPA); and next-generation sequencing (NGS)-for tumors that remain unclassified according to standard criteria. After review, 50 CD5-negative small B-cell lymphoid neoplasms without BCL2 and BCL6 FISH rearrangements were diagnosed as FLs (n = 27), NMZLs (n = 5), or unclassified (n = 18) based on the 2016 World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. FISH helped identify the 1p36 deletion in 3 FLs and 1 unclassified tumor. Most classified FLs had an RT-MLPA germinal center B-cell (GCB) signature (93%) or were noncontributive (7%). Classified NMZLs had an RT-MLPA activated B-cell signature (20%), had an unassigned signature (40%), or were noncontributive (40%). Among unclassified tumors, the RT-MLPA GCB signature was associated with mutations most commonly found in FLs (CREBBP, EZH2, STAT6, and/or TNFRSF14) (90%). An RT-MLPA-detected GCB signature and/or NGS-detected gene mutations were considered as FL identifiers for 13 tumors. An activated B-cell signature or NOTCH2 mutation supported NMZL diagnosis in 3 tumors. Combining the RT-MLPA and NGS findings successfully discriminated 89% of unclassified tumors in favor of one or the other diagnosis. NGS-detected mutations may be of therapeutic interest. Herein, we detected 3 EZH2 and 8 CREBBP mutations that might be eligible for targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, B-Cell, Marginal ZoneLymphoma, FollicularHumansIn Situ Hybridization, FluorescenceMultiplex Polymerase Chain ReactionHigh-Throughput Nucleotide SequencingChromosome DeletionDNA-Directed RNA PolymerasesProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcl-6

Stichwörter der Autor:innen

FISHNGSRT-MLPASmall B-cell lymphoid neoplasm

Substanzen

DNA-Directed RNA PolymerasesProto-Oncogene Proteins c-bcl-2BCL6 protein, humanProto-Oncogene Proteins c-bcl-6BCL2 protein, human

Autor:innen und Institutionen

  • Pathology Department, University Hospital of Bordeaux, Pessac, France. Electronic address: come.sesboue@chu-bordeaux.fr.
  • Hematology and Cell Therapy Department, University Hospital of Bordeaux, Pessac, France.
  • Pathology Department, University Hospital of Bordeaux, Pessac, France.
  • Tumor Bank and Tumor Biology Laboratory, University Hospital of Bordeaux, Pessac, France; BRIC INSERM U1312, Trio 2, University of Bordeaux, Bordeaux, France.
  • Tumor Bank and Tumor Biology Laboratory, University Hospital of Bordeaux, Pessac, France; BRIC INSERM U1312, BioGo, University of Bordeaux, Bordeaux, France.
  • Lausanne University Hospital, Lausanne, Switzerland.

Zitieren

APA

Sesboue, C., Galtier, J., Jeanneau, M., Chauvel, A., Laharanne, E., Amintas, S., Merlio, J. P., Bouabdallah, K., Gros, F. X., de Leval, L., Gros, A., & Parrens, M. (2023). Combined Reverse-Transcriptase Multiplex Ligation-Dependent Probe Amplification and Next-Generation Sequencing Analyses to Assign Unclassified BCL2/BCL6 Nonrearranged Small B-Cell Lymphoid Neoplasms as Follicular or Nodal Marginal Zone Lymphoma. Modern Pathology. https://doi.org/10.1016/j.modpat.2022.100043

Vancouver

Sesboue C, Galtier J, Jeanneau M, Chauvel A, Laharanne E, Amintas S, et al. Combined Reverse-Transcriptase Multiplex Ligation-Dependent Probe Amplification and Next-Generation Sequencing Analyses to Assign Unclassified BCL2/BCL6 Nonrearranged Small B-Cell Lymphoid Neoplasms as Follicular or Nodal Marginal Zone Lymphoma. Modern Pathology. 2023. doi:10.1016/j.modpat.2022.100043

BibTeX
@article{Sesboue2023,
  author = {Sesboue, Come and Galtier, Jean and Jeanneau, Marie and Chauvel, Annick and Laharanne, Elodie and Amintas, Samuel and Merlio, Jean-Philippe and Bouabdallah, Krimo and Gros, François-Xavier and de Leval, Laurence and Gros, Audrey and Parrens, Marie},
  title = {Combined Reverse-Transcriptase Multiplex Ligation-Dependent Probe Amplification and Next-Generation Sequencing Analyses to Assign Unclassified BCL2/BCL6 Nonrearranged Small B-Cell Lymphoid Neoplasms as Follicular or Nodal Marginal Zone Lymphoma},
  journal = {Modern Pathology},
  year = {2023},
  doi = {10.1016/j.modpat.2022.100043}
}
Kostenlos starten →